On 17 June 2015, the ACCC decided to accept an undertaking (the Zoetis undertaking) from Zoetis Inc., Zoetis Australia Pty Ltd, and Zoetis Australia Research & Manufacturing Pty Ltd and consented to a variation (the Pfizer variation) to the undertaking given by Pfizer Inc. and Pfizer Australia Pty Ltd and accepted by the ACCC on 30 September 2009 (the Pfizer undertaking).
On 21 May 2015 the Australian Competition and Consumer Commission (ACCC) accepted an undertaking pursuant to section 87B of the Competition and Consumer Act 2010 (the Act) given by Novion RE Limited and Novion Limited (Novion) (the Novion undertaking).
On 21 May 2015, the ACCC announced it had accepted undertakings from Federation Centres (Federation) and Novion Property Group (Novion) (the parties) in relation to Federation and Novion’s proposal to merge via a scheme of arrangement (Proposed Merger).
On 23 April 2015, the ACCC announced it had accepted an undertaking from Australian Amalgamated Terminals Pty Ltd (AAT) in relation to its proposed acquisition of a long term lease for the automotive and RoRo terminal at the Port of Fremantle (the proposed acquisition).
On 2 April 2015, the Australian Competition and Consumer Commission (ACCC) announced it had accepted an undertaking from Victoria Quay International RoRo Terminal Pty Ltd (VQIRT) in relation to its proposed acquisition of a long term lease for the automotive and RoRo terminal at the Port of Fremantle (the Proposed Acquisition).
On 28 January 2015 the ACCC accepted an undertaking (the Undertaking) given by GlaxoSmithKline Plc (GSK) and its subsidiary GlaxoSmithKline Australia Pty Ltd in relation GSK’s proposed acquisition of Novartis AG (Novartis)’s global human vaccine businesses (proposed acquisition).